Author argues Fate Therapeutics is a potential multi-bagger trading below cash with a decent pipeline and clinical trial catalysts in 2026.
FATE — LONG The author argues Fate Therapeutics is a potential multi-bagger, trading at $1 and below its cash value with a decent pipeline ahead of similar biotech peers. The catalyst is progress in clinical trials, with 2026 possibly being the company's year. The main risk is that the upside depends on clinical trial progress that may not materialize.
I believe this has some serious upside potential if they show some progress in their clinical trials.
This Reddit post, published January 14, 2026, features u/gtownguy123 discussing FATE. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/gtownguy123 · Tickers: FATE